Beyond the lab: immuno-oncology
14 February 2024
Shares
Read this in-depth analyses and insights from leading experts in the field focusing on treatments, new technologies and engineered bacteria.
Download this exclusive report to discover key immuno-oncology advancements and breakthroughs including targets playing crucial roles in multiple tumour survival pathways, how to improve the analysis of single-cell transcriptomic data and a new wave of promising NK cell therapeutics.
Expert insights from:
- Dr Catherine Pickering, CEO of iOnctura
- Dr Espen Basmo Ellingsen, University of Oslo
- Dr Tong Huo, Sino Biological
- Dr Vanda Lopes, BPS Bioscience
From the discovery of IOA-289, an autotaxin inhibitor with potential in pancreatic cancer therapy, to the development of Spectra, an open-source computational method revolutionising single-cell transcriptomic data analysis, this exclusive report showcases cutting-edge research and innovative approaches. Discover insights into macrophage phenotype optimisation for improved immunotherapy outcomes and mRNA therapies for glioblastoma demonstrate the evolving landscape of immune-based cancer treatments.
Download now to read more about:
- Combining autotaxin and TGF-β inhibitors in cancer
- New insights to improve immunotherapy treatments
- The promise of NK cell therapeutics
- Macrophage phenotype insights
- New technology optimising mesenchymal stem cell extraction
- Cancer-killing T cells enhanced by engineered bacteria.
Interested? Please register your details in the box to receive this exclusive content.
This Beyond the Lab report is brought to you in association with:
